PRESS RELEASE published on 11/27/2024 at 23:05, 1 year ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year ago Theralase Technologies conclut un placement privé de 666 400 $CAN Placement Privé Cancer De La Vessie Technologies Théralase Mandats Stade Clinique
BRIEF published on 11/15/2024 at 13:05, 1 year ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
BRIEF published on 11/13/2024 at 00:28, 1 year ago Theralase Technologies prolonge l'expiration du mandat jusqu'en 2027 Bourse De Croissance TSX Traitement Du Cancer Technologies Théralase Développement Pharmaceutique Prolongation Du Mandat
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 1 month ago Mises à jour de Theralase sur l'étude clinique sur le cancer de la vessie Approbation De La FDA Étude Clinique Theralase Cancer De La Vessie Ruvidar
BRIEF published on 10/07/2024 at 13:05, 1 year 1 month ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 1 month ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 12/05/2025 at 02:35, 5 hours 59 minutes ago Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 01:00, 7 hours 34 minutes ago BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 29 minutes ago BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 34 minutes ago NXT Energy Solutions Completes Data Acquisition for SFD Survey
Published on 12/05/2025 at 08:05, 29 minutes ago Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 33 minutes ago Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 33 minutes ago Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025
Published on 12/05/2025 at 08:00, 34 minutes ago Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) approaches the 500-million mark ahead of listing
Published on 12/05/2025 at 08:00, 34 minutes ago Le Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) croît et est sur le point de franchir la barre des 500 millions
Published on 12/04/2025 at 18:14, 14 hours 19 minutes ago Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 14 hours 34 minutes ago Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025
Published on 12/04/2025 at 18:00, 14 hours 34 minutes ago Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 49 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 12/04/2025 at 17:45, 14 hours 49 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
